About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our group aims to unravel the molecular mechanisms of cancer progression and metastasis to identify new diagnostic, prognostic and therapeutic targets in cancer. By combining the knowledge and availability of human tumors in the Pathology department with the expertise of the basic molecular cell biology research group, we focus on:
To evaluate the expression (nuclear and cytoplasmatic) of PTOV1 , Notch and Wnt on TMAs in c different histological types of carcinomas with low and high grades of malignancy . To correlate the inmunoexpression with classical parameters of tumor behaviour : tumoral size, grade of malignancy, vascular permeation, lymph nodes metastasis in each histological subtype and demonstrated the role of PTOV1 as predictive molecular marker in carcinomas.
(Research Biomedical Unit)
IP: Inés de Torres Ramirez
IP: Maria Mar Hernandez Guillamon Collaborators: Berta Paez Montserrat, Kerrie Adrián Campbell, Jessica Camacho Soriano, Anas Chaachou Charradi, Olalla Pancorbo Rosal Funding agency: Instituto de Salud Carlos III Funding: 208750 Reference: PI23/00082 Duration: 01/01/2024 - 31/12/2026
IP: Stefan Hummer Collaborators: Santiago Ramon y Cajal Agüeras, Elena Muro Blanc, Vicente Peg Camara, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras, Santiago Ramon y Cajal Agüeras Funding agency: Fundación Ramón Areces Funding: 127486 Reference: CIVP21S13325 Duration: 06/07/2023 - 05/07/2026
IP: Cleofé Romagosa Pérez-Portabell Collaborators: Xavier Martínez Gómez, Ximena Garcia Torres Funding agency: Asociación Española Contra el Cáncer Funding: 270130 Reference: ECAEC222952DEAL Duration: 01/12/2022 - 30/11/2027
IP: Trond Aasen Collaborators: Maria Rosa Somoza Lopez de Haro, Jordi Temprana Salvador, Teresa Moline Marimon, Marta Sese Faustino, Irene Sansano Valero, Stefan Hummer Funding agency: Instituto de Salud Carlos III Funding: 147620 Reference: PI21/00470 Duration: 01/01/2022 - 30/06/2026
The grants promote new therapeutic strategies and diagnostic tools in highly complex tumors such as glioblastoma, triple-negative breast cancer, and endometrial cancer.
The Department of Health of the Generalitat de Catalunya grants subsidies for carrying out validation tests on innovative projects in the field of health that are in the early stages of development.
The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.
Check the current rates for the services offered by the Translational Molecular Pathology research group.
Current Rates
PDF 0.25 MB
Rates Anatomia Patologica VHIR 2021
PDF 0.22 MB
